Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Clinical Study Shows That Retinal Imaging May Detect Signs of Alzheimer’s Disease

A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.

Read More »

Results from recent Alzheimer’s disease trials validate the ProMIS approach

ProMIS Neurosciences announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.”

Read More »

Lundbeck bets on shark antibodies for new brain drugs

Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer’s and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix.

Read More »

Lilly CEO Shakes Up Leadership Structure

Eli Lilly is looking to begin 2017 with a series of organizational changes that includes changes in some leadership roles.

Read More »

7 Juicy Acquisition Targets in Biopharma for 2017

2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.

Read More »

Congress passes sweeping new health bill

The U.S. Senate voted overwhelmingly to support sweeping legislation that will reshape the way the Food and Drug Administration approves new medicines.

Read More »

Allergan Buys Tobira for $1.695 Billion

In yet another buy in its string of acquisitions, Dublin-based Allergan announced it was acquiring San Francisco-based Tobira Therapeutics.

Read More »

Arena Forms Drug Discovery Incubator

San Diego-based Arena Pharmaceuticals announced that it had created an independent, privately held drug discovery incubator called Beacon Discovery.

Read More »

FDA moves Eisai Alzheimer’s drug to Phase III

Japan’s Eisai Co. said the U.S. FDA had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer’s disease.

Read More »

Alzheimer’s drug fails in study; some benefit seen

TauRx Pharmaceuticals’ experimental Alzheimer’s drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer’s disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom